Introduction Peptide-Oligonucleotide Conjugate Drug Product Formulation Services address the complex development transition between bulk active pharmaceutical ingredient (API) bioconjugation and […]
Introduction Peptide-oligonucleotide conjugates depend on Next-Generation Oligonucleotide Chemistries to address the limitations associated with native enzymatic degradation, inadequate cellular permeability,
Introduction Demonstrating bioequivalence for a Generic Topical Semisolid ANDA requires a comprehensive assessment of qualitative (Q1), quantitative (Q2), and structural
Introduction Selecting the appropriate Generic Peptide Regulatory Pathway—whether an Abbreviated New Drug Application (ANDA) under Section 505(j), a hybrid New
What Regulatory Pathway Do Generic Peptide Drugs Follow — ANDA, 505(b)(2), or BLA? Read More »
Introduction Executing compliant Impurity Control Strategies Under ICH Q3A and Q3B requires establishing scientific and toxicological parity with the Reference
Impurity Control Strategies Under ICH Q3A and Q3B for Generic Drug ANDA Submissions Read More »
Introduction Executing Generic Ophthalmic Suspension ANDA Development requires a coordinated technical strategy that integrates qualitative and quantitative sameness (Q1/Q2), structural
Introduction Designing a GMP-Compliant Extractables and Leachables (E&L) Study for container closure systems requires a systematic, risk-tiered analytical framework to
Introduction Extractables and Leachables (E&L) Requirements for Single-Use Bioprocessing in cell therapy programs define the analytical frameworks and risk assessment
Introduction Liquid chromatography-tandem mass spectrometry (LC-MS/MS) offers the sensitivity, mass accuracy, and structural resolution necessary for detecting, localizing, and quantifying
Introduction The fundamental Difference Between Biosimilar and Biologic Manufacturing from a quality perspective is rooted in the primary objective of
